BC Extra | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
Items per page:
1 - 1 of 1